ThromboGenics' current COO Patrik De Haes has been appointed to succeed Professor Désiré Collen as the company's new CEO. No specific reasons were given for the change, but Collen--who founded the company--will remain on the ThromboGenics' board of directors. De Haes will also be appointed to the board, and assumes his role as CEO on September 1.
- here's ThromboGenics' release